Atlas Trials

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Clinical trial NCT03161431 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03161431
Sponsor
Syntrix Biosystems, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Melanoma Stage IIIMelanoma Stage IV
Start date
2019-06-12
Primary completion
2026-08-01
Enrollment
77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.